Turnhout, 29 February 2008, Movetis NV, a European-based specialist pharmaceutical company, announced today the appointment of Dr Peter van Brummelen and Ferdinand Verdonck as Non-Executive Directors, effective immediately.
Dr Peter van Brummelen is an eminent scientist with extensive experience in the pharma and biotech industry. He currently sits on the Board of Directors of Basilea Pharmaceutica AG, (SWX: BSLN), Diatos SA, BioXell S.p.A. (SWX: BXLN), IQ Corporation B.V., CHDR (Academic CRO for clinical pharmacology) and Enceladus BV. He is also on the scientific advisory boards of Octoplus B.V. (Euronext: OCTO), and Thuja Capital B.V. and offers consultancy services to pharmaceutical and biotechnology companies, and venture capital firms. Formerly, he was the Executive Vice-President Research & Development for Yamanouchi Europe (1998-2003). From 1997 to 1998, he was Vice-President Clinical Research and Development and Chief Medical Officer at Solvay Pharmaceuticals and prior to that he worked at Hoffmann-La Roche, Inc from 1988 to1996, where he rose to become global Head of Clinical Pharmacology.
Ferdinand Verdonck is a financial expert with extensive experience in corporate finance and in the banking and financing community. He is currently a Non-Executive Director and a member of the board of Amsterdam Molecular Therapeutics BV (Euronext: AMT), a gene therapy-based company, Galapagos N.V. (Euronext, LSE: GLPG), a genomics based drug discovery company, the J.P Morgan European Investment Trust (LSE: JETG), Groupe SNEF, France, Laco Information Services, Belgium and Phoenix Funds, CT, USA. From 1992 to 2003, he was the Managing Director of Almanij N.V. (now merged with KBC Group), a diversified European financial services group. Before this, he was with N.V. Bekaert S.A., Belgium (1984 to1992) where he rose to become Corporate Vice President, Group CFO, Administration and Human Resources. Prior to this, he worked in the US at Lazard Frères & Company and at the Continental Illinois Bank, Chicago.
Staf Van Reet, Chairman of Movetis said, “We are delighted to have Ferdinand and Peter joining the Board. They bring extensive financial and scientific experience to the team, which will be invaluable in guiding the Company’s commercial and product strategy. We welcome them to the Board and look forward to working with them.”
